MAR 21, 2017 10:00 AM PDT

WEBINAR: Application of combined RNA in situ hybridization and multiplex immunohistochemistry to unravel tumor heterogeneity in prostate cancer

  • Associate Scientist, Henry Ford Health System
      Dr. Palanisamy completed his undergraduate and graduate studies at the University of Madras, India, and is currently an Associate/Senior Scientist at the Henry Ford Health System. He also holds an adjunct faculty appointment with the Michigan Center for Translational Pathology (MCTP) at the University of Michigan. His current research program is focused on the discovery of cancer biomarkers in lymphomas and solid cancers. During his post-doctoral research at the Memorial Sloan-Kettering Cancer Center, Dr. Palanisamy's work contributed to the discovery of recurrent gene fusions in follicular and diffuse large B-cell lymphomas. He was the founding Director of Research and Development at the Cancer Genetics, Inc (CGIX), where he introduced novel approaches to develop diagnostic reagents targeting chromosomal translocations in cancer. Dr. Palanisamy pioneered the application of next generation sequencing technology for transcriptome sequencing and discovered novel "druggable" gene fusions in prostate cancer, gastric cancer, and melanoma (Palanisamy et al., Nat Med 2010). His current research aims to understand the molecular basis of tumor heterogeneity in solid cancers, with particular focus on prostate cancer, and its impact in early diagnosis, response to treatment, and clinical outcome.
    • Senior Scientist, R&D, Advanced Cell Diagnostics
        Courtney is a senior scientist in R&D at Advanced Cell Diagnostics in Newark, California. In her current role, Courtney manages numerous projects with collaborators from around the globe to demonstrate new and exciting applications of the RNAscope and BaseScope technologies and their ability to detect RNA biomarkers with single-molecule sensitivity and single-cell resolution with morphological context. Prior to joining ACD, Courtney completed her postdoctoral studies in metabolic biology at the University of California Berkeley. Courtney received her Ph.D. in molecular and developmental biology from the University of California San Francisco and her B.A. in human biology from Brown University.


      DATE: March 21, 2017
      TIME: 10:00am PT, 1:00pm ET

      Sponsored By:


      Prostate cancer is a complex disease with multiple tumors originating independently at different stages of growth. Despite the identification of key morphological differences between individual tumor foci, the underlying molecular mechanisms driving growth within individual foci are often poorly understood. This is because traditional molecular and genetic studies involving systemic sampling of large tumor foci or high Gleason grade tumor foci often miss small tumor foci with important driver aberrations and high metastatic potential. To avoid overlooking foci with important driver aberrations, well-characterized cancer-specific markers can be used to screen the entire prostate tissue to assess molecular differences in individual tumor foci. A clearer understanding of foci-specific molecular heterogeneity is important, as these molecular differences may prognosticate tumor growth and treatment success. 

      In this presentation, we will demonstrate the power of dual immunohistochemistry (IHC) and in situ hybridization (ISH) as a technique to probe multiple cancer-specific molecular markers in the morphological context. Combining the protein detection capabilities of IHC with single-molecule mRNA expression analysis using RNAScope® ISH technology builds a more complete and robust picture of the molecular mechanisms governing individual tumor foci. In addition to highlighting the development of dual IHC/ISH to characterize solid tumor heterogeneity at the molecular level, we will present how high-sensitivity, single RNA molecule detection ISH combined with IHC can be applied to other biological questions to provide valuable information on the expression of molecular markers in nearly any biological pathway.   

      Learning Objectives:

      • Applying dual IHC/ISH methods
      • Understanding tumor heterogeneity

      Show Resources
      MAR 21, 2017 10:00 AM PDT

      WEBINAR: Application of combined RNA in situ hybridization and multiplex immunohistochemistry to unravel tumor heterogeneity in prostate cancer


      Cancer Research

      Molecular Biology

      Cell Biology


      Cancer Diagnostics

      Molecular Diagnostics




      Cancer Therapeutics

      Clinical Diagnostics

      Cell Culture


      Laboratory Testing

      Gene Expression


      North America58%



      South America2%



      Registration Source

      Website Visitors100%

      Job Title

      Research Scientist16%




      Post Doc10%

      Facility/Department Manager8%


      Medical Laboratory Technician5%

      Medical Doctor/Specialist5%

      Lab Management4%


      Clinical Laboratory Scientist2%




      Academic Institution11%

      Research Institute6%

      Biotech Company5%


      Clinical Laboratory4%

      Pharmaceutical Company3%

      Medical School2%

      Medical Center2%

      Life Science Company2%

      Ambulatory Care2%


      Contract Research Organization (Cro)1%

      Industrial Company1%

      Medical Device Company1%


      Show Resources
      Show Resources
      • See more
      Connect with us